Assessment of Circulating Copy Number Variant Detection for Cancer Screening

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2017 Jul 8

PMID 28686671

Citations 22

Authors

Bhuvan Molparia

Eshaan Nichani

Ali Torkamani

Affiliations

Soon will be listed here.

Abstract

Current high-sensitivity cancer screening methods, largely utilizing correlative biomarkers, suffer from false positive rates that lead to unnecessary medical procedures and debatable public health benefit overall. Detection of circulating tumor DNA (ctDNA), a causal biomarker, has the potential to revolutionize cancer screening. Thus far, the majority of ctDNA studies have focused on detection of tumor-specific point mutations after cancer diagnosis for the purpose of post-treatment surveillance. However, ctDNA point mutation detection methods developed to date likely lack either the scope or analytical sensitivity necessary to be useful for cancer screening, due to the low (<1%) ctDNA fraction derived from early stage tumors. On the other hand, tumor-derived copy number variant (CNV) detection is hypothetically a superior means of ctDNA-based cancer screening for many tumor types, given that, relative to point mutations, each individual tumor CNV contributes a much larger number of ctDNA fragments to the overall pool of circulating free DNA (cfDNA). A small number of studies have demonstrated the potential of ctDNA CNV-based screening in select cancer types. Here we perform an in silico assessment of the potential for ctDNA CNV-based cancer screening across many common cancers, and suggest ctDNA CNV detection shows promise as a broad cancer screening methodology.

Citing Articles

Analytical evaluation of circulating tumor DNA sequencing assays.

Li W, Huang X, Patel R, Schleifman E, Fu S, Shames D Sci Rep. 2024; 14(1):4973.

PMID: 38424110 PMC: 10904763. DOI: 10.1038/s41598-024-54361-w.

Non-invasive detection of lymphoma with circulating tumor DNA features and protein tumor markers.

Chang Y, Li S, Li Z, Wang X, Chang F, Geng S Front Oncol. 2024; 14:1341997.

PMID: 38313801 PMC: 10834776. DOI: 10.3389/fonc.2024.1341997.

A non-invasive method for concurrent detection of multiple early-stage cancers in women.

Gupta A, Siddiqui Z, Sagar G, Rao K, Saquib N Sci Rep. 2023; 13(1):19083.

PMID: 37925521 PMC: 10625604. DOI: 10.1038/s41598-023-46553-7.

A novel approach for the non-invasive diagnosis of pulmonary nodules using low-depth whole-genome sequencing of cell-free DNA.

Zhang B, Liang H, Liu W, Zhou X, Qiao S, Li F Transl Lung Cancer Res. 2022; 11(10):2094-2110.

PMID: 36386459 PMC: 9641036. DOI: 10.21037/tlcr-22-647.

Prognostic significance of copy number variation in B-cell acute lymphoblastic leukemia.

Song Y, Fang Q, Mi Y Front Oncol. 2022; 12:981036.

PMID: 35992882 PMC: 9386345. DOI: 10.3389/fonc.2022.981036.

References

Menon U, Gentry-Maharaj A, Hallett R, Ryan A, Burnell M, Sharma A . Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009; 10(4):327-40. DOI: 10.1016/S1470-2045(09)70026-9. View

Anders S, Pyl P, Huber W . HTSeq--a Python framework to work with high-throughput sequencing data. Bioinformatics. 2014; 31(2):166-9. PMC: 4287950. DOI: 10.1093/bioinformatics/btu638. View

Heitzer E, Ulz P, Belic J, Gutschi S, Quehenberger F, Fischereder K . Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. Genome Med. 2013; 5(4):30. PMC: 3707016. DOI: 10.1186/gm434. View

Imperiale T, Ransohoff D, Itzkowitz S, Levin T, Lavin P, Lidgard G . Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med. 2014; 370(14):1287-97. DOI: 10.1056/NEJMoa1311194. View

Hubbard R, Kerlikowske K, Flowers C, Yankaskas B, Zhu W, Miglioretti D . Cumulative probability of false-positive recall or biopsy recommendation after 10 years of screening mammography: a cohort study. Ann Intern Med. 2011; 155(8):481-92. PMC: 3209800. DOI: 10.7326/0003-4819-155-8-201110180-00004. View

Bettegowda C, Sausen M, Leary R, Kinde I, Wang Y, Agrawal N . Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014; 6(224):224ra24. PMC: 4017867. DOI: 10.1126/scitranslmed.3007094. View

Kandoth C, McLellan M, Vandin F, Ye K, Niu B, Lu C . Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502(7471):333-339. PMC: 3927368. DOI: 10.1038/nature12634. View

Abecasis G, Auton A, Brooks L, DePristo M, Durbin R, Handsaker R . An integrated map of genetic variation from 1,092 human genomes. Nature. 2012; 491(7422):56-65. PMC: 3498066. DOI: 10.1038/nature11632. View

Chan K, Jiang P, Zheng Y, Liao G, Sun H, Wong J . Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing. Clin Chem. 2012; 59(1):211-24. DOI: 10.1373/clinchem.2012.196014. View

10.

Heidary M, Auer M, Ulz P, Heitzer E, Petru E, Gasch C . The dynamic range of circulating tumor DNA in metastatic breast cancer. Breast Cancer Res. 2014; 16(4):421. PMC: 4303230. DOI: 10.1186/s13058-014-0421-y. View

11.

Erikson G, Deshpande N, Kesavan B, Torkamani A . SG-ADVISER CNV: copy-number variant annotation and interpretation. Genet Med. 2014; 17(9):714-8. PMC: 4886732. DOI: 10.1038/gim.2014.180. View

12.

Bolger A, Lohse M, Usadel B . Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics. 2014; 30(15):2114-20. PMC: 4103590. DOI: 10.1093/bioinformatics/btu170. View

13.

Fan H, Gu W, Wang J, Blumenfeld Y, El-Sayed Y, Quake S . Non-invasive prenatal measurement of the fetal genome. Nature. 2012; 487(7407):320-4. PMC: 3561905. DOI: 10.1038/nature11251. View

14.

Nygren A, Dean J, Jensen T, Kruse S, Kwong W, Van Den Boom D . Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem. 2010; 56(10):1627-35. DOI: 10.1373/clinchem.2010.146290. View

15.

Leary R, Sausen M, Kinde I, Papadopoulos N, Carpten J, Craig D . Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing. Sci Transl Med. 2012; 4(162):162ra154. PMC: 3641759. DOI: 10.1126/scitranslmed.3004742. View

16.

Kirkizlar E, Zimmermann B, Constantin T, Swenerton R, Hoang B, Wayham N . Detection of Clonal and Subclonal Copy-Number Variants in Cell-Free DNA from Patients with Breast Cancer Using a Massively Multiplexed PCR Methodology. Transl Oncol. 2015; 8(5):407-416. PMC: 4631096. DOI: 10.1016/j.tranon.2015.08.004. View

17.

Singleton M, Guthery S, Voelkerding K, Chen K, Kennedy B, Margraf R . Phevor combines multiple biomedical ontologies for accurate identification of disease-causing alleles in single individuals and small nuclear families. Am J Hum Genet. 2014; 94(4):599-610. PMC: 3980410. DOI: 10.1016/j.ajhg.2014.03.010. View

18.

Punglia R, DAmico A, Catalona W, Roehl K, M Kuntz K . Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003; 349(4):335-42. DOI: 10.1056/NEJMoa021659. View

19.

Beroukhim R, Mermel C, Porter D, Wei G, Raychaudhuri S, Donovan J . The landscape of somatic copy-number alteration across human cancers. Nature. 2010; 463(7283):899-905. PMC: 2826709. DOI: 10.1038/nature08822. View

20.

Zack T, Schumacher S, Carter S, Cherniack A, Saksena G, Tabak B . Pan-cancer patterns of somatic copy number alteration. Nat Genet. 2013; 45(10):1134-40. PMC: 3966983. DOI: 10.1038/ng.2760. View